WT1 2-Log Reduction After Induction Therapy Predicts Outcomes in Acute Myeloid Leukemia Patients

The WT1 gene is overexpressed in 80–90% of acute myeloid leukemia (AML) cases, and its expression has been associated with several molecular alterations, i.e., FLT3 and NPM1 mutations, representing a complementary marker for prognostic assessment and measurable residual disease (MRD) monitoring. However, its clinical and prognostic significance in AML has not yet been fully clarified. We retrospectively evaluated WT1 expression at diagnosis and its possible value in MRD assessment in AML patients treated with intensive chemotherapy at the Hematology Units of Siena and Ravenna. WT1 transcript levels were quantified in bone marrow samples at diagnosis and post-induction therapy by standardized RT-qPCR. This study involved 120 AML patients; according to ELN 2022, 44 (36.7%) patients were classified as adverse, 50 (41.7%) as intermediate, and 26 (21.7%) as favorable risk. Median WT1 expression was 4559 copies/104 ABL1 at diagnosis and 122 copies/104 ABL1 after induction therapy. A post-induction WT1 reduction of >2 logs was significantly associated with improved overall survival (OS) and event-free survival, as well as prolonged time to relapse. Combining WT1 reduction with FLT3 status further stratified OS, with the poorest outcome observed in patients with <2-log reduction and persistent FLT3 positivity. Changes in WT1 levels, especially a >2-log reduction after induction therapy, could provide complementary MRD information in AML, including for patients lacking leukemia-specific molecular targets.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-16
DOI
https://doi.org/10.3390/ijms272210287
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

WT1 2-Log Reduction After Induction Therapy Predicts Outcomes in Acute Myeloid Leukemia Patients

Monica Bocchia, Margherita Malchiodi, Sara Monti, Beatrice Anna Zannetti et al.
2 links
International Journal of Molecular Sciences
Acute Myeloid Leukemia Research
article

WT1 2-Log Reduction After Induction Therapy Predicts Outcomes in Acute Myeloid Leukemia Patients

Monica Bocchia, Margherita Malchiodi, Sara Monti, Beatrice Anna Zannetti, Michela Rondoni, Francesco Lanza, Giovanni Marconi, Serena Rocchi, Alessandra Cartocci, Anna Sicuranza, Adele Santoni, Teresa Miracapillo, Camilla Turriziani, Cristina Marzano, Karim Palombo, Mariachiara Cuccaro
article en

Abstract

The WT1 gene is overexpressed in 80–90% of acute myeloid leukemia (AML) cases, and its expression has been associated with several molecular alterations, i.e., FLT3 and NPM1 mutations, representing a complementary marker for prognostic assessment and measurable residual disease (MRD) monitoring. However, its clinical and prognostic significance in AML has not yet been fully clarified. We retrospectively evaluated WT1 expression at diagnosis and its possible value in MRD assessment in AML patients treated with intensive chemotherapy at the Hematology Units of Siena and Ravenna. WT1 transcript levels were quantified in bone marrow samples at diagnosis and post-induction therapy by standardized RT-qPCR. This study involved 120 AML patients; according to ELN 2022, 44 (36.7%) patients were classified as adverse, 50 (41.7%) as intermediate, and 26 (21.7%) as favorable risk. Median WT1 expression was 4559 copies/104 ABL1 at diagnosis and 122 copies/104 ABL1 after induction therapy. A post-induction WT1 reduction of >2 logs was significantly associated with improved overall survival (OS) and event-free survival, as well as prolonged time to relapse. Combining WT1 reduction with FLT3 status further stratified OS, with the poorest outcome observed in patients with <2-log reduction and persistent FLT3 positivity. Changes in WT1 levels, especially a >2-log reduction after induction therapy, could provide complementary MRD information in AML, including for patients lacking leukemia-specific molecular targets.

International Journal of Molecular SciencesVol. 27(22)
University of Siena (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Azienda Ospedaliera Universitaria Senese (IT), University of Bologna (IT)
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon